玛兹度肽在中国2型糖尿病患者中的疗效与安全性:一项随机、双盲、安慰剂对照的2期试验
这项随机、双盲、安慰剂对照2期试验评估每周一次玛兹度肽(胰高血糖素样肽1和胰高血糖素受体双重激动剂)在中国2型糖尿病患者中的疗效与安全性。患者随机接受3 mg、4.5 mg、6 mg玛兹度肽、1.5 mg开放标签度拉糖肽或安慰剂皮下注射20周。玛兹度肽使HbA1c降低1.41%至1.67%,体重降低最多7.1%,最常见不良事件为腹泻(36%)、食欲下降(29%)、恶心(23%)、呕吐(14%)和低血糖(10%)。
要点
- 玛兹度肽20周使HbA1c较基线降低1.41%至1.67%,安慰剂组升高0.03%(P<0.0001)。
- 玛兹度肽体重降幅呈剂量依赖性,最高达7.1%;度拉糖肽组降低2.7%,安慰剂组降低1.4%。
- 玛兹度肽组达到HbA1c<7.0%和≤6.5%及体重降低≥5%和≥10%的比例高于安慰剂组。
核心结论
- 在中国2型糖尿病患者中,玛兹度肽剂量至6 mg总体安全,并显示出有临床意义的HbA1c和体重降低。
研究设计与样本
- 随机、双盲、安慰剂对照2期试验。
- 饮食和运动控制不佳或联用稳定剂量二甲双胍、HbA1c 7.0-10.5%(53-91 mmol/mol)的成人2型糖尿病患者随机接受3 mg玛兹度肽(n=51)、4.5 mg玛兹度肽(n=49)、6 mg玛兹度肽(n=49)、1.5 mg开放标签度拉糖肽(n=50)或安慰剂(n=51)皮下注射20周。
- 主要结局为HbA1c从基线至第20周的变化。
主要发现
- HbA1c从基线至第20周的平均变化:玛兹度肽组为-1.41%至-1.67%,度拉糖肽组为-1.35%,安慰剂组为0.03%(所有玛兹度肽组 vs 安慰剂 P<0.0001)。
- 体重从基线至第20周的平均百分比变化呈剂量依赖性,玛兹度肽组最高达-7.1%,度拉糖肽组为-2.7%,安慰剂组为-1.4%。
- 第20周时,与安慰剂组相比,玛兹度肽组参与者更可能达到HbA1c<7.0%(53 mmol/mol)和≤6.5%(48 mmol/mol)以及体重较基线降低≥5%和≥10%。
- 玛兹度肽最常见不良事件包括腹泻(36%)、食欲下降(29%)、恶心(23%)、呕吐(14%)和低血糖(10%[安慰剂组8%])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol/mol]) were randomly assigned to receive 3 mg mazdutide (n = 51), 4.5 mg mazdutide (n = 49), 6 mg mazdutide (n = 49), 1.5 mg open-label dulaglutide (n = 50), or placebo (n = 51) subcutaneously for 20 weeks. The primary outcome was change in HbA1c from baseline to week 20. RESULTS: Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide (-1.35% with dulaglutide and 0.03% with placebo; all P < 0.0001 vs. placebo). Mean percent changes in body weight from baseline to week 20 were dose dependent and up to -7.1% with mazdutide (-2.7% with dulaglutide and -1.4% with placebo). At week 20, participants receiving mazdutide were more likely to achieve HbA1c targets of <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) and body weight loss from baseline of ≥5% and ≥10% compared with placebo-treated participants. The most common adverse events with mazdutide included diarrhea (36%), decreased appetite (29%), nausea (23%), vomiting (14%), and hypoglycemia (10% [8% with placebo]). CONCLUSIONS: In Chinese patients with type 2 diabetes, mazdutide dosed up to 6 mg was generally safe and demonstrated clinically meaningful HbA1c and body weight reductions.
引用
- Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024. PMID: 37943529. doi:10.2337/dc23-1287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。